COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia. Study Design: Cross sectional comparative...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Army Medical College Rawalpindi
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d8f0d65f3f354ee8a7f84f9724a06ee8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia.
Study Design: Cross sectional comparative study.
Place and Duration of Study: The present study was conducted in the Medicine Department, Pakistan Naval Ship, Shifa Hospital, Karachi, from Mar to Sep 2016.
Methodology: The sample was collected by non- probability convenient sampling. The total of 114 DM type 2 patients were randomly divided into two equal groups. Group A was given Rosuvastatin whereas group B was given Atorvastatin orally daily for 12 weeks along with oral treatment for diabetes. After 12 weeks, Fasting Serum Total Cholesterol and Serum LDL-C were estimated, and noted as final levels.
Results: There was greater reduction in terms of mean change in serum total cholesterol levels and low-density lipoprotein – cholesterol (LDL-C) levels with Rosuvastatin as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.
Conclusion: Rosuvastatin can significantly improve lipid profile as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia. |
|---|